Problem

Clinical-trial recruitment is a costly bottleneck for pharmaceutical sponsors, research sites, and patients. Trially says 86% of trials are delayed by recruitment failures, costing sponsors more than $600,000 per day, while research sites can spend more than 250 hours each month manually reviewing charts against increasingly complex eligibility criteria. The core opportunity is to uncover eligible patients already represented in clinical data rather than relying mainly on advertising and labor-intensive screening.

The killer use case is a research site running a complex trial that needs to identify qualified participants quickly, reduce screen failures, and convert matches into actual enrollments. Trially’s case studies describe a site network that had enrolled only one patient in 18 months and then enrolled six times more patients in four months using Trially.

Product / Service

Trially is a HIPAA-compliant AI platform for clinical-trial patient recruitment. Its LLM agents analyze structured and unstructured medical data, including EHR information, to match patients against trial eligibility criteria. Trially Match identifies likely candidates, while Trially Connect—and its agentic AI product Margo—uses outreach and pre-screening to turn qualified matches into enrolled participants.

The platform is designed to fit existing research workflows through connectors to EHRs, clinical-trial management systems, CRMs, and other patient lists. Trially reports approximately 95% screening accuracy, two-to-six times more monthly enrollment in complex trials, 73% fewer screen failures, and 91% less billable time spent on manual chart review. It states that the product supports HIPAA, SOC 2, FDA 21 CFR Part 11, IRB, and ISO 27001 requirements.

Market

Trially competes in AI-enabled clinical-trial patient recruitment and enrollment software, serving research sites, hospitals, pharmaceutical sponsors, CROs, and physician networks. Its closest named competitors include Deep 6 AI, BEKHealth, and SelectIQ. The category sits at the intersection of clinical-trial technology, healthcare data interoperability, AI-assisted patient matching, and recruitment automation.

Trially announced a $4.7 million seed round in September 2025 and the launch of Margo. Its public case studies report outcomes including six-times higher enrollment in four months, $4 million in awarded study revenue for a site-network case, and substantially lower screening and chart-review effort. These are evidence of customer or partner traction, but the public materials reviewed do not disclose Trially’s own revenue, customer count, or contract value, so it is more accurate to describe the company as funded and showing reported commercial traction than to claim a verified revenue scale or label it definitively pre-revenue.